Juliano Alves has a PhD in Pharmacology from the University of São Paulo and was a researcher at the Genomics Institute of the Novartis Research Foundation and the Scripps Research Institute.
He is currently a senior researcher at Promega Corporation where he worked on the development of several technologies used in drug discovery.